QIAGEN Concludes Business Combination Agreement With EQT Private Equity
QIAGEN also disclosed preliminary third-quarter 2026 results and suspended its full-year 2026 outlook.
Story updates
09:35:56 PM UTC
SquawkNews
QIAGEN entered a deal with EQT-led Crown NL Bidco for a voluntary tender offer at €46.50/share, valuing it at ~€10.8B EV. Q3 2026 preliminary sales were $548M and adjusted diluted EPS $0.65; full-year 2026 outlook suspended. Closing is expected mid-2027, subject to conditions.Material DetailsContex…
09:44:14 PM UTC
SquawkNews
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER.QIAGEN plans to report full Q…
09:44:59 PM UTC
SquawkNews
QIAGEN reported preliminary Q3 2026 net sales of $548M (reported and CER) and adjusted diluted EPS of $0.65 (also CER). The company suspended its full-year 2026 outlook due to the pending EQT Private Equity transaction.Material DetailsContext by AI AnalystThis is a preliminary flash ahead of full Q…
QIAGEN N.V. / Key word(s): Mergers and Acquisitions / Sale of Business Units/Results / QuarterQIAGEN N.V.: Conclusion of a Business Combination Agreement with EQT Private Equity; preliminary Q3 2026 results and suspension of full-year 2026 outlook21-Oct-2026 / 23:32 CET/CESTDisclosure of an inside…